Soligenix, Inc. (Soligenix), incorporated on January 16, 1987, is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. The Company's BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate. The development of its vaccine programs is supported by heat stabilization technology, known as ThermoVax.
BioTherapeutics
SGX301 is a first-in-class, photodynamic therapy that utilizes safe visible light for activation. The active ingredient in SGX301 is synthetic hypericin, a photosensitizer, which is topically applied to skin lesions and then activated by fluorescent light 16 to 24 hours later. Hypericin is also found in several species of Hypericum plants, although the drug used in SGX301 is chemically synthesized by a manufacturing process and not extracted from plants. Hypericin is optimally activated with visible light thereby avoiding the negative consequences of ultraviolet light. Other light therapies using ultraviolet A (UVA) light result in serious adverse effects, including secondary skin cancers. Combined with photoactivation in clinical trials, hypericin has demonstrated anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.
SGX94 is an innate defense regulator (IDR) that regulates the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing. SGX94 is based on a class of short, synthetic peptides known as IDRs that have a mechanism of action in that it is simultaneously anti-inflammatory and anti-infective. IDRs represent an approach to the control of infection and tissue damage through a selective binding to an intracellular adaptor protein, sequestosome-1, also known as p62, which has a function in signal transduction during activation and control of the innate defense system. SGX94 has demonstrated efficacy in numerous animal disease models, including mucositis, colitis, skin infection and other bacterial infections.
SGX942 is its product candidate containing its IDR technology platform, SGX94, targeting the treatment of oral mucositis in head and neck cancer patients. Accordingly, it received Fast Track designation for the treatment of oral mucositis as a result of radiation or chemotherapy treatment in head and neck cancer patients. The Company is conducting a Phase II clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer patients.
Vaccines/BioDefense
The Company's thermostability technology, ThermoVax, is a method of rendering aluminum salt, (known colloquially as Alum), adjuvanted vaccines stable at elevated temperatures. Proof-of-concept preclinical studies with ThermoVax indicate that it is able to produce stable vaccine formulations using adjuvants, protein immunogens and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.
The Company competes with Celtaxsys Inc., Innaxon Therapeutics, Innate Pharma SA, Daewoong Pharmaceutical Co., Ltd, Cellceutix Corporation, BioAlliance Pharma S.A., Onexeo, Alder Biopharmaceuticals Inc., ActoGenix N.V., Bill and Melinda Gates Foundation, PATH, Stabilitech Ltd., Variation Biotechnologies, Inc., PaxVax, Inc., Pharmathene, Inc., Panacea Biotec Ltd., Compass Biotech Inc., The U.S. Army Medical Research Institute of Infectious Diseases, Cleveland Biolabs, Inc., Aeolus Pharmaceuticals, Inc., Boulder Biotechnology, Inc., RxBio, Inc., Avaxia Biologics, Inc., Exponential Biotherapies Inc., Osiris Therapeutics, Inc., ImmuneRegen BioSciences, Inc., Neumedicines, Inc., Cellerant Therapeutics, Inc., Onconova Therapeutics, Inc., Araim Pharmaceuticals, Inc., EVA Pharmaceuticals, Terapio Corporation, Cangene Corporation, Humanetics Corporation and the University of Arkansas Medical Sciences Center.
29 Emmons Dr Ste C10
The company trades on NASDAQ exchange. The company headquarter is located in New Jersey, NJ. The company was established in the 1987.| Ticker | SNGX |
| Long Name | Soligenix, Inc. |
| Short Name | Soligenix |